Provided by Tiger Trade Technology Pte. Ltd.

ArriVent BioPharma

27.97
-0.6000-2.10%
Post-market: 27.970.00000.00%19:30 EDT
Volume:337.27K
Turnover:9.45M
Market Cap:1.38B
PE:-7.56
High:28.75
Open:28.51
Low:27.70
Close:28.57
52wk High:35.83
52wk Low:17.00
Shares:49.31M
Float Shares:32.11M
Volume Ratio:0.52
T/O Rate:1.05%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.6975
EPS(LYR):-4.3239
ROE:-53.25%
ROA:-33.11%
PB:3.76
PE(LYR):-6.47

Loading ...

ArriVent BioPharma, Inc. (AVBP) Gets a Buy from Guggenheim

TIPRANKS
·
Yesterday

Analysts Offer Insights on Healthcare Companies: Cellectis SA (CLLS) and ArriVent BioPharma, Inc. (AVBP)

TIPRANKS
·
Yesterday

Analysts Are Bullish on Top Healthcare Stocks: Revolution Medicines (RVMD), ArriVent BioPharma, Inc. (AVBP)

TIPRANKS
·
Yesterday

ArriVent’s ARR-002 Moves Forward in Early Ovarian and Endometrial Cancer Study

TIPRANKS
·
Sep 04

Arrivent Biopharma, Inc. : H.c. Wainwright Raises Target Price to $47 from $44

THOMSON REUTERS
·
Aug 17

U.S. Research Roundup- Berkshire Hathaway, Exxon Mobil, Honeywell Technologies

Reuters
·
Aug 17

ArriVent BioPharma (AVBP) Could Be 56% Undervalued After The Allist China Licensing Deal

Simply Wall St.
·
Aug 16

ArriVent BioPharma: Pipeline Progress and Funding Strength Support Buy Rating and Unchanged $42 Price Target

TIPRANKS
·
Aug 13

ArriVent BioPharma Price Target Maintained with a $42.00/Share by BTIG

Dow Jones
·
Aug 13

ArriVent BioPharma, Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 13

ArriVent Biopharma Releases Corporate Presentation on Late-Stage Oncology Pipeline Led by Firmonertinib in EGFR-Mutant NSCLC

Reuters
·
Aug 13

ArriVent inks China partnership for ARR-002 development

TIPRANKS
·
Aug 13

ArriVent BioPharma Q2 EPS $(1.05) Misses $(0.99) Estimate

Benzinga Earnings
·
Aug 13

Press Release: ArriVent BioPharma Reports Second Quarter 2026 Financial Results

Dow Jones
·
Aug 13

Analysts Are Bullish on These Healthcare Stocks: Astrana Health (ASTH), ArriVent BioPharma, Inc. (AVBP)

TIPRANKS
·
Jul 14

ArriVent BioPharma Stockholders Back Board and Auditor Slate

TIPRANKS
·
Jun 23

ArriVent Biopharma shareholders elect Class II directors at annual meeting

Reuters
·
Jun 23

ArriVent’s MRG007 Phase I Trial Progress Adds Long-Term Option Value for AVBP Investors

TIPRANKS
·
Jun 05

Analysts Offer Insights on Healthcare Companies: Veeva Systems (VEEV), Mineralys Therapeutics, Inc. (MLYS) and ArriVent BioPharma, Inc. (AVBP)

TIPRANKS
·
Jun 04

Guggenheim Remains a Buy on ArriVent BioPharma, Inc. (AVBP)

TIPRANKS
·
Jun 02